(PRKAG2 syndrome as a highly arrhythmogenic eventuality in the differential diagnosis of hypertrophic cardiomyopathy - an example of two families with a confirmed causative DNA variant)
M. Hodboďová, A. Krebsová, P. Peldová, R. Polášek, T. Roubíček
{"title":"(PRKAG2 syndrome as a highly arrhythmogenic eventuality in the differential diagnosis of hypertrophic cardiomyopathy - an example of two families with a confirmed causative DNA variant)","authors":"M. Hodboďová, A. Krebsová, P. Peldová, R. Polášek, T. Roubíček","doi":"10.33678/cor.2022.116","DOIUrl":null,"url":null,"abstract":"Hypertrophic cardiomyopathy (HCM) affects 0.2% of the population and is the most common form of here- ditary heart muscle disease in adults. The most frequent cause of HCM are changes in the genes encoding sarcomere proteins. However, up to 10% of patients are affected by another type of systemic genetic dis- ease that has myocardial hypertrophy as only one of its multi-organ manifestations. Among these diseases is PRKAG2 glycogenosis, a rare metabolic storage disorder caused by an inherited defect in the 2 regula-tory subunit of adenosine monophosphate-activated protein kinase (AMPK). In addition to skeletal muscle myopathy, it causes HCMP with a high risk of malignant ventricular and supraventricular arrhythmias and several conduction disorders. Thanks to close collaboration of several departments, we diagnosed two families with a causative DNA variant in the PRKAG2 gene. On the basis of the presented case studies, we document highly variable manifestations of PRKAG2 syndrome and thus highlight the pitfalls in its clinical diagnosis and therapy","PeriodicalId":10787,"journal":{"name":"Cor et vasa","volume":null,"pages":null},"PeriodicalIF":0.2000,"publicationDate":"2023-06-20","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Cor et vasa","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.33678/cor.2022.116","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q4","JCRName":"CARDIAC & CARDIOVASCULAR SYSTEMS","Score":null,"Total":0}
引用次数: 0
Abstract
Hypertrophic cardiomyopathy (HCM) affects 0.2% of the population and is the most common form of here- ditary heart muscle disease in adults. The most frequent cause of HCM are changes in the genes encoding sarcomere proteins. However, up to 10% of patients are affected by another type of systemic genetic dis- ease that has myocardial hypertrophy as only one of its multi-organ manifestations. Among these diseases is PRKAG2 glycogenosis, a rare metabolic storage disorder caused by an inherited defect in the 2 regula-tory subunit of adenosine monophosphate-activated protein kinase (AMPK). In addition to skeletal muscle myopathy, it causes HCMP with a high risk of malignant ventricular and supraventricular arrhythmias and several conduction disorders. Thanks to close collaboration of several departments, we diagnosed two families with a causative DNA variant in the PRKAG2 gene. On the basis of the presented case studies, we document highly variable manifestations of PRKAG2 syndrome and thus highlight the pitfalls in its clinical diagnosis and therapy